logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Comprehensive commitment of the pharmaceutical industry to patient safety

Clinical trials, pharmacovigilance and verification are just some of the fields of action where pharmaceutical companies actively work to guarantee the well-being of people in their relationship with medicines.

Source: www.consalud.es

The increased complexity in healthcare and the constant and improved evolution of personalized treatments have made it necessary for all the agents that make up the health sector to focus on patient safety, with the aim of preventing and reducing risks, errors and potential damages that people may suffer during the provision of health care.

Patient safety is essential to provide quality essential health services. In fact, there is a clear consensus that quality health services around the world must be effective, safe and people-centered. For this reason, the World Health Organization (WHO) decided last year to dedicate a day to awareness of patient safety: September 17.

The use of medicines, as well as infections related to health care, diagnostic errors or surgical complications, has been considered as one of the fields of action where there is room for improvement and surveillance plans must be strengthened to avoid unnecessary damage to the patients.

The use of medicines, as well as infections related to health care, diagnostic errors or surgical complications, has been considered one of the fields of action where there is room for improvement
In this sense, the pharmaceutical industry has been committed for years to patient safety in all areas that have to do with research, development, manufacture, marketing and proper use of medicines.

Thus, safety in the research process is fully guaranteed by an ethical and legal framework in both the European and national environment, with Directive 2001/20 / EC and RD 1090/2015, the Declaration of Helsinki on medical research in human beings, the International Guide to Good Clinical Practice or the Global Vaccine Safety Initiative (GVSI).

This regulatory framework allows the participation of healthy and sick people in any of the phases that comprise clinical trials to prove the safety and efficacy of drugs have all the guarantees and that pharmacological research is a solid and reliable process.

SECURITY IN THE TREATMENTS AGAINST COVID-19

One of the evidence that best supports this reality is found today in the race undertaken by industry, governments and research centers to find a pharmacological solution to the SARS-CoV-2 pandemic, which is significantly reducing the times of R&D process of potential vaccines and treatments. Today it can be said that the safety of the research is not being compromised and, in no case, will the urgency to find an effective vaccine or drug against the coronavirus prevail over the safety of the people.

Nine pharmaceutical companies, leaders in vaccine research and manufacturing, stated this just a week ago through a joint manifesto in which they committed to developing vaccines in accordance with “ethical standards and sound scientific principles” that have always been characterized the research of these drugs. “The safety and efficacy of vaccines, including any potential vaccine for Covid-19, is reviewed and determined by expert regulatory agencies around the world (…). They will only be submitted for approval or authorization for emergency use when their safety and efficacy are demonstrated through a phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities, ”the statement said.

“The safety and efficacy of vaccines, including any potential vaccine for Covid-19, is reviewed and determined by expert regulatory agencies around the world”

According to the WHO, greater patient involvement is essential for safer health care, so, “if done right, it can reduce the burden of harm on delivery by up to 15%, saving billions of dollars every year”. In Spain, Farmaindustria has promoted this same year, in the hands of patient organizations and pharmaceutical companies, a guide of recommendations to strengthen the participation of patients in the research process, in order to provide it with even more security from the knowledge and transparency all along the way.

Likewise, the pharmaceutical industry works with one of the highest quality standards in the manufacture and production of medicines of all industrial sectors, being able to detect any possible errors or contamination in batches in short periods of time and withdrawing the product before that it reaches the market on many occasions.

ACTIVE ROLE OF THE INDUSTRY IN PHARMACOVIGILANCE

In terms of patient safety, it is also worth highlighting the active role that pharmaceutical companies have in pharmacovigilance, which has been reinforced in recent years with the update in 2010 of the European Directive on the matter, as well as with the RD 577/2013. To both standards is added the guide to good practices in pharmacovigilance for the pharmaceutical industry, which includes an exhaustive control of possible adverse drug reactions, the periodic review of scientific evidence or immediate communication to the health authorities of any change in the benefit-risk balance of the drug, among many other control measures.

Finally, the innovative pharmaceutical sector is also committed to patient safety once the drug is placed on the market through the anti-counterfeiting system, a European legislative initiative that in Spain is managed through the Spanish Drug Verification System (SEVeM) , in which pharmaceutical companies, distribution and pharmaceutical associations collaborate. The entry into force of the regulation reached its first year of life last February and its ultimate goal is to further increase surveillance within the drug supply chain.

Patient safety is the main thing at this time and we believe it at Distefar. The pharmaceutical industry has always had this very present and at times like the ones we are going through, this security increases.

Related entries

4 October, 2023

“Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.


Leer más
2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más

Recent Posts

  • “Artificial intelligence and technology are driving digital therapies, which benefit not only patients, but the healthcare system and society as a whole”.
  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.